ArticleInternational journal of retina and vitreous2026
Automated diabetic retinopathy grading and screening using deep learning.
Article in International journal of retina and vitreous, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo develop and benchmark a unified Deep Learning (DL) pipeline for automated detection and five-level grading of Diabetic Retinopathy (DR), and to derive a high-performance binary screening endpoint (DR vs No DR) suitable for scalable use in resource-limited settings.
methodsA publicly available five-class DR fundus dataset of 3,500 color photographs graded using the International Clinical Diabetic Retinopathy (ICDR) scale was used. A standardized workflow was applied across eight Convolutional Neural Network (CNN) architectures (AlexNet, Densely Connected Convolutional Network 121 (DenseNet121), Residual Network 50 (ResNet50), eXtreme Inception (Xception), Mobile Network Version 2 (MobileNetV2), Efficient Network Version 2 B2 (EfficientNetV2B2), Inception Version 3 (InceptionV3), Visual Geometry Group 16 (VGG16)), including a 70/20/10 train/validation/test split, optional histogram-based contrast enhancement, strong on-the-fly augmentations, and class-balanced sampling. Seven architectures (DenseNet121, ResNet50, Xception, MobileNetV2, EfficientNetV2B2, InceptionV3, and VGG16) were initialized using ImageNet-pretrained weights and trained using a two-stage transfer-learning strategy with backbone freezing followed by partial fine-tuning, while AlexNet was implemented as a custom architecture and trained from randomly initialized weights.
resultsFor five-class grading, VGG16 achieved the highest accuracy (0.7686) and weighted Jaccard index (0.6572), while EfficientNetV2B2 provided the best balanced accuracy (0.6128) and macro Area Under the Receiver Operating Characteristic Curve (AUROC 0.9158). Misclassifications were concentrated between adjacent severity levels. For binary DR screening, modern backbones achieved ≥0.94 accuracy and balanced accuracy; selected models reached AUROC ≈0.982-0.990 and Area Under the Precision-Recall Curve (AUPRC) ≈ 0.987-0.992.
conclusionThe proposed DL pipeline delivers robust multiclass DR grading and highly discriminative binary screening using widely available CNN backbones. Operating-point calibration enables sensitivity-oriented triage or specificity-oriented confirmation, supporting teleophthalmology and task-shifted DR screening programs to expand coverage and reduce preventable vision loss. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.